{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T01:46:00Z","timestamp":1767836760785,"version":"3.49.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.diagmicrobio.2012.08.022","type":"journal-article","created":{"date-parts":[[2012,9,28]],"date-time":"2012-09-28T00:55:17Z","timestamp":1348793717000},"page":"89-93","source":"Crossref","is-referenced-by-count":11,"title":["Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: selecting potent surrogate \u03b2-lactam markers to predict ceftaroline activity against clinically indicated species"],"prefix":"10.1016","volume":"75","author":[{"given":"Ronald N.","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew G.","family":"Stilwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2012.08.022_bb0005","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1128\/JCM.25.8.1570-1571.1987","article-title":"Cross susceptibility and absence of cross resistance to cefotetan and cefoxitin","volume":"25","author":"Barry","year":"1987","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2012.08.022_bb0010","series-title":"Performance standards for antimicrobial disk susceptibility tests; approved standard -- 11th edition, M02-A11","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2012"},{"key":"10.1016\/j.diagmicrobio.2012.08.022_bb0015","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard -- ninth edition, M07-A9","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2012"},{"key":"10.1016\/j.diagmicrobio.2012.08.022_bb0020","series-title":"Performance standards for antimicrobial susceptibility testing: 23rd informational supplement (M100-S23)","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2013"},{"key":"10.1016\/j.diagmicrobio.2012.08.022_bb0025","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1086\/655827","article-title":"Integrated analysis of CANVAS 1 and 2: Phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection","volume":"51","author":"Corey","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2012.08.022_bb0030","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1086\/657313","article-title":"Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia","volume":"51","author":"File","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2012.08.022_bb0035","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/S0968-0896(03)00126-3","article-title":"TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties","volume":"11","author":"Ishikawa","year":"2003","journal-title":"Bioorg Med Chem"},{"issue":"Suppl. 3","key":"10.1016\/j.diagmicrobio.2012.08.022_bb0040","first-page":"iii69","article-title":"Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: Results from an international surveillance study","volume":"66","author":"Jones","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2012.08.022_bb0045","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ijantimicag.2010.04.013","article-title":"Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia","volume":"36","author":"Jones","year":"2010","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl. 4","key":"10.1016\/j.diagmicrobio.2012.08.022_bb0050","first-page":"iv17","article-title":"Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study","volume":"65","author":"Jones","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2012.08.022_bb0055","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0732-8893(01)00229-2","article-title":"Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin? Report from The SENTRY Antimicrobial Surveillance Program (1997\u20131999)","volume":"39","author":"Jones","year":"2001","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2012.08.022_bb0060","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1128\/JCM.00576-06","article-title":"Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program","volume":"44","author":"Jones","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2012.08.022_bb0065","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.diagmicrobio.2007.10.018","article-title":"Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem","volume":"59","author":"Jones","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2012.08.022_bb0070","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.diagmicrobio.2010.08.024","article-title":"Declining antimicrobial susceptibility of Streptococcus pneumoniae in the United States: report from the SENTRY Antimicrobial Surveillance Program (1998\u20132009)","volume":"68","author":"Jones","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2012.08.022_bb0075","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0732-8893(93)90041-5","article-title":"Prediction of bacterial susceptibility to cefpodoxime by using the ceftriaxone minimum inhibitory concentration result","volume":"17","author":"Jones","year":"1993","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"Suppl. 3","key":"10.1016\/j.diagmicrobio.2012.08.022_bb0080","first-page":"iii3","article-title":"Changing needs of community-acquired pneumonia","volume":"66","author":"Ramirez","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2012.08.022_bb0085","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1128\/AAC.49.8.3501-3512.2005","article-title":"Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains","volume":"49","author":"Sader","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2012.08.022_bb0090","unstructured":"Teflaro Package Insert 2012. New York City, NY. Accessed June 2012. Available online: http:\/\/www.frx.com\/pi\/Teflaro_pi.pdf."},{"key":"10.1016\/j.diagmicrobio.2012.08.022_bb0095","author":"US-FDA"},{"key":"10.1016\/j.diagmicrobio.2012.08.022_bb0100","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2165\/00003495-200969070-00003","article-title":"Ceftaroline: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus","volume":"69","author":"Zhanel","year":"2009","journal-title":"Drugs"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889312003513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889312003513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T07:30:48Z","timestamp":1594711848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889312003513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0732889312003513"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2012.08.022","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}